Novel compounds as IAP antagonists
By developing a compound that can bind to and inhibit its activity, the problem of difficulty in designing highly effective IAP protein inhibitors in the prior art is solved, and effective treatment of diseases related to IAP protein overexpression is achieved.
CN119638702APending Publication Date: 2025-03-18ASCENTAGE PHARMA SUZHOU CO LTD +1
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202411298551.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-29
- Filing Date
- 2024-09-18
- Publication Date
- 2025-03-18
AI Technical Summary
Technical Problem
It is difficult to design efficient IAP protein inhibitors for the treatment of diseases related to IAP protein overexpression, such as various types of cancer.
Method used
A novel compound has been developed to inhibit its activity by binding to IAP proteins (especially cIAP1, cIAP2 or XIAP), thereby providing a method for the treatment of IAP-related diseases.
Benefits of technology
This compound effectively inhibits the activity of IAP proteins and provides potential treatment options for the treatment of IAP-related diseases, especially in cancer treatment.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to compounds that inhibit IAP (preferably cIAP1, cIAP2, or XIAP) protein, pharmaceutical compositions comprising the compounds and methods of using the IAP protein inhibitors in the treatment of diseases and conditions in which inhibition of IAP protein provides a benefit.
Need to check novelty before this filing date? Find Prior Art